AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02791841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Hemispheric-Specific Stimulation + Action Video Games
Description: This training combines Visual Hemisphere-Specific Stimulation (VHSS) according to Bakker's Balance Model, and Action Video-Games (AVG). Hemispheric-specific stimulation is carried out by tachistoscopic presentation of words to a visual hemifield in order to selectively stimulate right-hemisphere perceptual analysis or left-hemisphere linguistic anticipation. A computerized program is used, in which the word is flashed and presented for less than 350 ms only if the child clicks on the mouse at the exact moment a dot is crossing a central target (control of eye position and fixation).~AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used.
Study NCT02791841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Video Games
Description: AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used.
Study NCT02461160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-915 suspension
Description: TAK-915 oral suspension
Study NCT02461160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam oral solution
Study NCT02461160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching TAK-915 suspension
Study NCT02461160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-915 tablet
Description: TAK-915 tablet
Study NCT04185389 — intervention group
Intervention type: OTHER
Intervention: HPV and cytology co-testing (via Liquid based collection device)
Description: Liquid-based cytology co-testing is a procedure in which that a cervical sample is taken, and can be co-tested for HPV and standard cytology at the same time. It is collected in the same way that a traditional Pap is collected
Study NCT01748058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise based on active video gaming
Study NCT03153423 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Strabismus surgery
Description: Recession and resection of horizontal extra ocular muscles
Study NCT02290405 — intervention group
Intervention type: BEHAVIORAL
Intervention: Multiple Sleep Latency Test (MSLT)
Description: The daytime protocol will include a 4-trial Multiple Sleep Latency Test (MSLT) along with 4-trials of a computer -administered battery of reaction time tasks. The assessment protocol will start two to three hours after participants' respective morning rising times and will begin with a battery of the neuro-cognitive testing followed by an MSLT nap. Per standard MSLT procedures, the daytime testing will be scheduled so the four performance testing and sleepiness assessment trials occur two hours apart. All daytime testing will be conducted under the supervision of trained laboratory technologists.
Study NCT01776255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Children, Strong Families
Description: Healthy Children, Strong Families is a series of 13 lessons mailed to primary caregivers of preschool aged children that provide education and activities related to obesity prevention. The lessons cover topics related to nutrition, physical activity, stress, sleep, and the home environment. Lessons include printed materials and small items (for example, an apple sectioner) that support activities in the lessons. Social support components via a monitored Facebook group and approximately semiweekly text messages sent to caregivers are included. The intervention spans 1 year.
Study NCT01776255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Children, Strong Families
Description: Healthy Children, Strong Families is a series of 13 lessons mailed to primary caregivers of preschool aged children that provide education and activities related to obesity prevention. The lessons cover topics related to nutrition, physical activity, stress, sleep, and the home environment. Lessons include printed materials and small items (for example, an apple sectioner) that support activities in the lessons. Social support components via a monitored Facebook group and approximately semiweekly text messages sent to caregivers are included. The intervention spans 1 year.
Study NCT01776255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child Safety
Description: The Child Safety intervention is an active control condition consisting of monthly two-page newsletters covering various topics relevant to child safety such as choking, car safety seats, bike and pedestrian safety. The intervention spans 1 year.
Study NCT01776255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Safety
Description: The Child Safety intervention is an active control condition consisting of monthly two-page newsletters covering various topics relevant to child safety such as choking, car safety seats, bike and pedestrian safety. The intervention spans 1 year.
Study NCT01288404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorometholone
Description: topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks
Study NCT01288404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: subconjunctival bevacizumab 1.25 mg/0.05mL
Study NCT01288404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: subconjunctival bevacizumab 2.5 mg/0.1mL
Study NCT01288404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: subconjunctival bevacizumab 3.75 mg/0.15mL
Study NCT02323828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High RS cookies
Description: High RS cookies ingestion in healthy young adults
Study NCT02323828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cookies ingestion in healthy young adults
Study NCT01561846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CLA enriched cheese
Description: This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
Study NCT01561846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CLA enriched cheese
Description: This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
Study NCT02892552 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cone Beam Computed Tomography (CBCT)
Description: Patients had an additional Cone Beam Computed Tomography, after the usual MDCT
Study NCT04456374 — intervention group
Intervention type: OTHER
Intervention: Performance testing
Description: Soccer-specific performance will be evaluated by measuring flexibility, jumping ability, maximum speed, repeated spring ability, agility and endurance.
Study NCT02665273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Greater occipital nerve block
Description: Bilateral greater occipital nerve block
Study NCT01383590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: Intradermal injection 1 x 4 administrations 4 weeks apart.
Study NCT02892552 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multiple Detector Computed Tomography (MDCT)
Description: Patients had a usual MDCT, before having an additional Cone Beam Computed Tomography
Study NCT00693095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-ALT + CMV-DCs
Description: CMV-ALT (3 X 10e7) with CMV-DCs (2 X 10e7)
Study NCT00693095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-ALT + Saline
Description: CMV-ALT (3 X 10e7) with Saline
Study NCT02905032 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: Observation of clinical encounter using the electronic decision aid to facilitate treatment option conversation between clinician and patient.
Study NCT04201197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inje cocktail
Description: Acute drug exposure
Study NCT04201197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inje cocktail
Description: Acute drug exposure
Study NCT04201197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC Cannabis extract
Description: Acute drug exposure
Study NCT04201197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC/CBD Cannabis Extract
Description: Acute drug exposure
Study NCT02829476 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Osteoblast sample
Description: culture osteoblasts obtained from vertebrae fragments from 30 patients with AIS and from 10 control patients with secondary scoliosis
Study NCT02206360 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic Ultrasound
Study NCT02206360 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Study NCT02046603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 52 weeks.
Study NCT02046603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study. The study protocol does not specify any particular therapy.
Study NCT02046603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Corticosteroids
Description: Stable oral corticosteroids doses (≤10 mg/day prednisone or equivalent) are allowed. The study protocol does not specify any additional detail on types of oral corticosteroids.
Study NCT04251845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: topical melatonin
Description: Topical melatonin at 3% concentration with dosage of 15 mg once daily will be applied on the lesion for 6 weeks followed by a follow up of 3 months
Study NCT04251845 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Topical application of placebo once daily for 6 weeks with a follow up for 3 months
Study NCT03191097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingavirin
Description: Ingavirin capsules 60 mg once daily, regardless of meal, for 5 days.
Study NCT03191097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo, capsules daily for 5 days.
Study NCT01453764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Harvesting and Implantation of SVF
Description: The cell therapy in this study is composed of stem cells derived from a patient's own adipose tissue that are harvested by liposuction using tumescent technique and isolated in the laboratory. The Adipose SVF will be delivered via intravenous injection.
Study NCT01174472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Description: Angioplasty performed with the use of the novel paclitaxel eluting balloons
Study NCT01174472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Description: Angioplasty performed with the use of conventional angioplasty balloons
Study NCT02046603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate per investigator's discretion.
Study NCT01843738 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Per standard of care
Study NCT02665273 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bupivacaine
Description: 0.5 cc of 0.5% bupivacaine injected intradermally
Study NCT04627805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPath tool
Description: MyPath is a reproductive decision support tool that utilizes a patient-centered approach to help women frame their reproductive decisions in the context of their goals, preferences, and health needs. This tool was developed by Dr. Lisa Callegari with funding from the Veterans Administration (VA) Health Services Research \& Development to be used in primary care settings with women veterans. It is conceptually grounded in Self-Determination Theory, which postulates that health care that meets patients' psychological needs in three key domains - autonomy, competence, and relatedness - will result in improved health behaviors and health outcomes. This is particularly relevant in reproductive health care, given the highly individualized and personal nature of these decisions, and the importance of centering a woman's aspirations and goals in her health care decision making.
Study NCT01843738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: The starting dose of vemurafenib will be the patient's baseline tolerating dose, between 720 - and 960 mg PO bid.
Study NCT02164305 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No exercise training
Study NCT01548131 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Psychoeducative group therapy
Description: 6 sessions during pregnancy and 1 after childbirth
Study NCT01548131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducative group therapy
Description: 6 sessions during pregnancy and 1 after childbirth
Study NCT04482504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3 tests: Posturography, Questionnaire, vitamin D
Description: Posturography platform Kistler 9281B Questionnaire focused on exercise activities and self-evaluation of postural stability The investigators also determine level of vitamin D in the blood.
Study NCT03414216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 1 early offloading surgery
Description: As above.
Study NCT03555227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG PECS2 with Drug A (active)
Description: Ultrasound guided Pecs 2 blocks with 0.25% levobupivacaine
Study NCT04020133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: saphenous nerve block
Description: The skin is disinfected and the saphenous nerve is located via Ultrasound . the transducer is placed anteromedially, approximately at mid-thigh level a high-frequency linear probe 5Y12 MHz prepared in a sterile fashion (Phillips HD11) .~The block needle (Stimuplex; Braun Medical, Bethlehem, Pa), is inserted in plane in a lateral-to-medial orientation and advanced toward the femoral artery .Once the needle tip is visualized anterior to the artery and after careful aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site . When injection of local anesthetic does not appear to result in its spread around the femoral artery, additional needle repositions and injections may be necessary.
Study NCT04020133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: popliteal plexus block
Description: After doing saphenous nerve block , we will move distally with the artery in the adductor canal until it moves away from the sartorius muscle to enter adductor hiatus . here , we will inject L.A above artery and so , popliteal plexus block will be accomplished
Study NCT03555227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG PECS2 with Drug P (placebo)
Description: Ultrasound guided Pecs 2 blocks with placebo (0.9% saline)
Study NCT04020133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plain bupivacaine
Description: 15ml of plain bupivacaine 0.5% will be given in both blocks
Study NCT03555227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration with Drug P (placebo)
Description: Wound infiltration at the end of surgery with Drug P (0.9% saline)
Study NCT04020133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05 mg epinephrine
Description: 0.05 mg epinephrine will be added to bupivacaine in both blocks to prolong their duration
Study NCT03555227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration with Drug A (active)
Description: Wound infiltration at the end of surgery with 0.25% levobupivacaine
Study NCT03589794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AP10-602
Description: Glucopyranosyl Lipid A -liposome-Quillaja Saponaria 21 (GLA-LSQ).
Study NCT04529200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrotherapy treatment
Description: physical therapy management like EMS IFT
Study NCT04382131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaCl Solution
Description: NaCl Solution prepared by participants at home using water and salt
Study NCT01995084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]HX4
Description: 400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
Study NCT03733288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and training sessions
Description: Agents will be invited to attend sessions in intervention week 1, 3, 9, and month 6. Sessions will introduce (week 1) and reinforce (week 3, 9, month 6) the intervention aims, benefits of and ways to move more and sit less, with emphasis on active breaks. Feedback from baseline assessment will be provided and discussed in week 3 (health data) and 9 (activity data) and month 6 (health and activity data from the 12-week assessment). Each session will include discussion of daily standing/walking goals set by the research team, with timers and a goal log provided to participants in week 1 to enable self-monitoring. The Stand Up champions, and their role to encourage daily movement and sitting reduction through modelling and verbal support, will be communicated and reinforced in each session.
Study NCT03733288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support emails
Description: Agents will receive support emails weekly (weeks 1-12) then monthly (months 4-9) across the intervention. Each email includes an infographic that encourages moving more and sitting less at work.
Study NCT03733288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team leader training
Description: Team leaders in the participating organisation will be invited to attend a training session before the intervention starts. The training aims to enhance team leader's capabilities to demonstrate positive movement and sitting behaviours at work and promote call agents to sit less and move more at work. Team leaders will be asked to include the intervention as an agenda item in their weekly team meetings with their call agents and their 1:1 sessions with call agents. Team leaders will be encouraged to incorporate walking into their 1:1 meetings with call agents.
Study NCT03733288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Height-adjustable workstation
Description: After baseline, agents in the SLAMM+ arm will have a height-adjustable workstation installed on their existing workplace desk. This will enable work in a seated or standing position, with flexibility to alternate between postures. Desk installation will occur with support from the onsite organisation health and safety team. The research team will brief participants on safe and effective workstation use. A laminated sheet will be fixed to each workstation to remind participants of safe and effective use.
Study NCT01530295 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DOCETAXEL
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 3 times pre-op and 3 times after surgery
Study NCT01530295 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: DOCETAXEL
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 3 times pre-op and 3 times after surgery
Study NCT03409926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acacia Gum
Description: dietary supplement will be added to the participant's usual diet
Study NCT03409926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acacia Gum
Description: dietary supplement will be added to the participant's usual diet
Study NCT02520011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib
Study NCT02520011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02520011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Study NCT02520011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study NCT02520011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone